Nanovaccine trains immune cells to hunt lung cancer
NCT ID NCT07239544
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new way to create tumor-reactive T cells for people with non-small cell lung cancer. Researchers use a nanovaccine made from lung cancer antigens to train T cells to attack the cancer. The goal is to see if these T cells can effectively target tumors in lab models and in the body. The study involves 50 participants and focuses on understanding how the T cells behave after being reinfused.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor whole cell antigen nanovaccine and tumor-reactive T cells
What this could lead to
If successful, this could lead to a more effective and personalized cell therapy for non-small cell lung cancer, potentially improving tumor targeting and patient outcomes.
What could go wrong
This is an early-stage observational study with only 50 participants, so results may not apply broadly. The approach is complex and may face challenges in effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Soochow university
Suzhou, Jiangsu, 215000, China